By selecting an indication, you certify that you are a licensed healthcare professional.
Please see Important Safety Information presented throughout this site and Full Prescribing Information.
By selecting an indication, you certify that you are a licensed healthcare professional.
Please see Important Safety Information presented throughout this site and Full Prescribing Information.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
In PALACE™ 1
38% ACR20 response with Otezla 30 mg
twice daily (n=168)
vs 19% with placebo (n=168) at week 16
(primary endpoint; P=0.0001)
In ESTEEM® 1
33% PASI-75 response with Otezla 30 mg
twice daily (n=562)
vs 5% with placebo (n=282) at week 16
(primary endpoint; P<0.0001)
In RELIEF™, reduced pain and number of oral ulcers were seen with Otezla 30 mg twice daily (n=104) vs placebo (n=103) at week 12.
In RELIEF, the endpoints were:
Safety profile: The most common adverse reactions (≥10%) were diarrhea, nausea, headache, and upper respiratory tract infection.1
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for Full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for Full Prescribing Information.